Physician profile
Stephen I Rennard
NPI 1023068053
$49,736.50
in general payments reported to CMS, 2019-2025
10 companies · $17K in 2025
The $17K reported for 2025 was more than what 95% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,825 · 2021: $16K · 2023: $10K · 2024: $4,374 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,420 · Travel and Lodging: $1,325 · Food and Beverage: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,131.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,420.00 |
| Travel and Lodging | $1,324.54 |
| Food and Beverage | $194.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $19,679.84 | 2021-2024 | |
| Galvanize Therapeutics, INC | $10,966.67 | 2025 | Aliya System |
| Sanofi-Aventis U.S. LLC | $6,589.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $4,033.49 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,825.00 | 2020 | |
| Roche Sequencing Solutions, INC. | $1,722.50 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,545.00 | 2021 | |
| Eli Lilly and Company | $1,400.00 | 2025 | |
| Beyond Air, INC. | $1,000.00 | 2023 | Lungfit |
| Ucb Sa | $975.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Rennard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.